Learn how symptoms, repeat testosterone tests, SHBG and sampling conditions fit together in the EAU approach to diagnosing late-onset hypogonadism.
Symptoms and testosterone blood tests provide different kinds of evidence, and diagnosing late-onset hypogonadism depends on how those findings fit together.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret personal symptoms and laboratory results and make decisions about diagnosis or treatment.
Symptoms describe the clinical concern that testosterone testing is intended to assess. They help establish whether a man's experience fits a possible testosterone deficiency rather than simply identifying whether a laboratory number falls outside a range.
The European Association of Urology (EAU) recommends assessing late-onset hypogonadism through compatible symptoms or signs together with consistently low testosterone. Its guidance recommends screening for this condition in symptomatic men rather than using testosterone testing as a general search for low numbers.
The EAU lists several sexual symptoms among the more specific features associated with hypogonadism:
Fatigue, low mood, sleep disturbance and reduced energy may also be reported. However, the guideline stresses that symptoms associated with hypogonadism are not unique to it. A clinician therefore considers the broader health picture rather than assuming that a familiar symptom identifies its cause.
This is also why an online symptom score is not equivalent to a clinical assessment. The EAU says symptom questionnaires have poor specificity and should not be used for systematic screening. In practical terms, a questionnaire may record concerns without reliably distinguishing testosterone deficiency from other explanations.
The useful distinction is between describing a problem and proving its hormonal basis. Symptoms give the assessment a clinical focus; blood testing supplies a separate form of evidence. Testostra's explanation of connecting symptoms with laboratory findings develops that distinction further.
A testosterone blood test provides biochemical evidence: the measured testosterone concentration in a sample. Unlike a symptom history, it gives a numerical result that can be considered against a laboratory reference interval and clinical guidance.
The EAU requires low morning total testosterone on at least two occasions alongside compatible clinical findings. It also specifies reliable assays and fasting samples. The result therefore needs a testing history and methodological context, not just a label saying “low.”
The EAU identifies total testosterone of 12 nmol/L (3.5 ng/mL) as a reliable threshold for late-onset hypogonadism. It recommends repeat measurement when a result is below that level.
That is a guideline-specific threshold rather than a universal diagnostic number. It belongs within the EAU's wider assessment of symptoms and confirmed biochemical findings. It should not be separated from those requirements and treated as an automatic treatment boundary.
A laboratory reference interval and a clinical diagnostic threshold also serve different roles in interpretation. The EAU notes that commercial immunoassay reference information may not clearly identify the population used to establish it or the quality of sampling conditions. This makes the laboratory's method and reference information relevant to the clinical discussion.
The practical question is not simply whether a number is marked outside the laboratory range. It is how the clinician interprets that number using the applicable guidance and the person's health context.
The EAU recommends morning testing, generally between 07:00 and 10:00. After an initially abnormal result, it calls for a confirmatory measurement before testosterone therapy.
Sleep patterns are relevant to that timing. For night-shift workers, the guideline notes that sleep drives the daily testosterone rhythm and recommends sampling after adequate sleep. A clock time alone does not capture that person's testing circumstances.
Fasting status matters too. The EAU cites evidence that non-fasting measurements can underestimate total testosterone by more than 30% in some circumstances. This is not a fixed correction that can be added to an individual result; it supports using appropriate sampling conditions rather than adjusting the number at home.
The guideline also advises against measuring testosterone during acute illness. It recommends considering other health conditions and reviewing drugs or substances that may interfere with testosterone production or action.
For a clinical conversation, the useful information includes when the sample was collected and whether it was fasting. Sleep patterns and health at the time also belong in that account. These details help explain why a testosterone measurement needs context before it is treated as a lasting finding.
The EAU identifies LC-MS/MS as the most accurate method for evaluating sex steroids. It also notes that standardized automated immunoassays for total testosterone correlate well with that method.
That distinction does not mean every result obtained through an immunoassay should be dismissed. It means the method and its standardization belong in interpretation. The guideline encourages close collaboration between clinicians and laboratories to support accurate and comparable testosterone measurements.
Free testosterone testing requires its own attention to method. The EAU advises against direct free-testosterone immunoassays. A report labelled “free testosterone” therefore needs more context than the test name alone.
The EAU describes free testosterone assessment as potentially useful when sex hormone-binding globulin, or SHBG, is altered. It identifies obesity as a factor associated with lower SHBG and ageing as a factor associated with higher SHBG.
These associations explain why a clinician may consider more than total testosterone in selected circumstances. They do not make free testosterone an automatic replacement for total testosterone or remove the need for compatible clinical findings.
When discussing a result, the relevant question is why SHBG or free testosterone would add useful information in that particular assessment. Testostra's guide to interpreting borderline laboratory findings provides further educational context for that discussion.
Symptoms and laboratory findings are complementary rather than competing ways to diagnose the same condition. In the EAU framework, the clinical assessment establishes whether the presentation is compatible with hypogonadism. Properly obtained blood tests establish whether low testosterone is consistently present.
Reading them together changes the question from “Is this number low?” to “Does the full pattern support this diagnosis?” That shift keeps the assessment focused on the person rather than on an isolated laboratory flag.
Compatible symptoms together with repeatedly low morning testosterone fit the EAU's diagnostic framework. The next clinical task includes evaluating the cause rather than assuming that confirmation has answered every question.
The guideline recommends LH and FSH assessment to help distinguish types of hypogonadism. It also includes prolactin testing in the stated clinical context. These related measurements serve a different purpose from simply repeating total testosterone: they contribute to understanding the underlying explanation.
This is where interpreting LH and FSH alongside testosterone becomes relevant. The purpose is to connect the results rather than read each hormone as an unrelated number.
If symptoms are present but biochemical confirmation is missing, the unresolved issue is the relationship between those findings. The EAU framework directs attention to reliable testing and the broader clinical picture. SHBG and free testosterone may be relevant when the guideline's stated conditions apply.
If a low number is present but compatible symptoms or signs have not been established, the clinical part of the assessment still needs attention. A laboratory flag does not replace that part of the diagnostic process.
These situations are reasons for a focused discussion with a qualified clinician. Useful questions concern whether the result has been confirmed and whether sampling conditions were appropriate. The assay method and the possible value of related biomarkers are further points for discussion when relevant.
Under EAU guidance, confirmation of an initially abnormal testosterone result comes before testosterone therapy. Establishing a diagnostic pattern and choosing treatment are therefore distinct clinical decisions.
The assessment also includes relevant health conditions and possible interference from drugs or substances. Where testosterone is abnormal, further evaluation helps clarify the cause. Those steps give a clinician information that the original testosterone number does not supply by itself.
For someone reviewing a first result, the practical aim is to understand what evidence is already available and what remains unresolved. That may concern repeat testing or the conditions under which the sample was taken. It may also concern whether the clinical findings and related biomarkers support the same explanation.
Personal treatment choices belong with qualified care rather than being inferred from a cutoff or symptom score.
Symptoms and testosterone measurements belong in one clinical assessment, with health context and reliable confirmation giving both their meaning.
A flagged total testosterone result raises a practical question about whether SHBG and free testosterone also matter, which Testostra addresses through evidence-led biomarker education. Its explanations connect these related measurements so readers can understand laboratory terminology and prepare informed questions without treating an article as a personal diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra